Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05923203 · ClinicalTrials.gov registry record · NA

Combined Electric and Acoustic Hearing (EAS) in Children and Adults

A NA study of Hearing Loss and Cochlear Implant, sponsored by Hearts for Hearing.

Recruiting
Registry status
NA
Development phase
160
Enrollment target
4
Study locations

NCT05923203: Recruiting NA study of Hearing Loss and Cochlear Implant, sponsored by Hearts for Hearing.

NCT05923203 is a NA study of Hearing Loss and Cochlear Implant that is actively recruiting participants, run by Hearts for Hearing. The registered enrollment target is 160 participants, below the 6,118-participant average among 58 other Hearing Loss trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05923203, a NA study of Hearing Loss and Cochlear Implant, is actively recruiting participants, sponsored by Hearts for Hearing.

RECRUITING
Registry status
NA
Development phase
160 participants
Enrollment target
4
Study locations

Study Summary

Cochlear implants are surgically implanted devices which restore the ability to hear to the hearing impaired. Improvements in surgery and electrodes have results in an increased number of adults and children who have residual hearing and can benefit from electric and acoustic hearing in the same ear. This is called Electric Acoustic Stimulation (EAS). Many studies have shown that adult EAS users show significant benefits for speech understanding in noise and spatial hearing tasks as compared to a CI paired only with a contralateral HA. Even though this type of hearing is becoming more common, there is limited research on how it can be beneficial to children with CIs. The benefits of this study are a greater understanding of the participant's speech understanding, binaural processing, and spatial hearing. The results will help audiologists and researcher better understand how cochlear implants work, specifically when using electric and acoustic hearing in the same ear.

Primary Outcome

Speech recognition will be assessed with co-located (S0N0) and spatially separated noise (S0N90 and S0N270) using the BEL sentences with two different male or female talkers as the maskers. Target speech will be fixed at 70 dB SPL for both speech stimuli and the investigators will assess performance for two listening conditions: CI+HA and CIHA+HA.

Interventions

  • OTHER Electric and acoustic stimulation (EAS) technology in the implanted ear(s)-this is the combination of a cochlear implant (CI) and hearing aid (HA) in the implanted ear(s)

Study Locations (4)

Oklahoma

  • Hearts for Hearing - Edmond

Tennessee

  • Vanderbilt University Medical Center - Nashville

Texas

  • University Of Texas at Austin - Austin

Wisconsin

  • University Of Wisconsin Madison - Madison

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2022-12-05
Est. Completion 2028-08-31
Phase NA
Hearts for Hearing

2 total trials

What NCT05923203 shows while recruiting

NCT05923203 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 6,118-participant average among 58 other Hearing Loss trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Hearing Loss appearing as the primary indexed condition, and to 1 intervention - of which Electric and acoustic stimulation (EAS) technology in the implanted ear(s)-this is the combination of a cochlear implant (CI) and hearing aid (HA) in the implanted ear(s) is the first listed.

NCT05923203 reports a single indexed study location in Oklahoma, Tennessee, Texas.

Frequently Asked Questions

What is clinical trial NCT05923203 about?

NCT05923203 is a clinical study titled "Combined Electric and Acoustic Hearing (EAS) in Children and Adults". Cochlear implants are surgically implanted devices which restore the ability to hear to the hearing impaired. Improvements in surgery and electrodes have results in an increased number of adults and children who have residual hearing and can benefit from electric and acoustic hearing in the same ear...

What is the current status of trial NCT05923203?

This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2022-12-05. Estimated completion is 2028-08-31.

What conditions does trial NCT05923203 study?

This clinical trial studies the following conditions: Hearing Loss, Cochlear Implant.

What interventions are being tested in trial NCT05923203?

The interventions under investigation include: Electric and acoustic stimulation (EAS) technology in the implanted ear(s)-this is the combination of a cochlear implant (CI) and hearing aid (HA) in the implanted ear(s) (OTHER).

Who is sponsoring clinical trial NCT05923203?

This trial is sponsored by Hearts for Hearing, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05923203 being conducted?

This trial has 4 study locations across Oklahoma, Tennessee, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hearing Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05923203's enrollment target sits among peer trials

160 26th of 58 higher than 33 of 58 other Hearing Loss trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05923203, the US trial registry maintained by the National Library of Medicine. NCT05923203 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.